Sensorium Therapeutics
Alex Simon has had a varied career trajectory, beginning with their role as a Global Shaper for the World Economic Forum in 2011. Alex then joined Compass Partners as an Executive Director and Director of Strategic Partnerships from 2011-2016. In 2016, they began working at Oscar Insurance as a Network Expansion Project, and simultaneously at YNG Ventures as a Co-Founder, where they helped to launch YPO Next Gen, an organization for the children of Young Presidents Organization (YPO) members. Alex also joined NextGen Venture Partners as a Venture Partner in 2016. In 2017, they became a Partner at Wonderland Investments, and in 2018 they joined Alto Essentials as a Partner. In 2020, they began working as an Advisor for the Center for the Neuroscience of Psychedelics at the Massachusetts General Hospital, and in 2021 they became Co-Founder and Chief Of Staff at Sensorium Therapeutics.
Alex Simon completed their education history with a Master's program in Chairs from the Open Master's Program between 2012-2014. Prior to that, they obtained a Bachelor's Degree in International Relations and Affairs from The George Washington University between 2008-2012. Alex began their education journey in 2004 at Newton North High School, where they obtained their High School Degree.
This person is not in the org chart
This person is not in any offices
Sensorium Therapeutics
Founded by world-class researchers, clinicians, and thought leaders from Massachusetts General Hospital and Harvard University, Sensorium Therapeutics is a biotechnology company leveraging cutting-edge chemistry, neuroscience, and machine learning to develop nature-derived psychoactive medicines for mental health. Inspired by the real-world human benefits of plants and fungi, Sensorium’s groundbreaking Biodynamic Discovery Platform leverages cutting-edge chemistry, neuroscience, and machine learning to reproduce, adapt, and enhance targeted molecules to elevate their utility as modern medicines that can deliver transformational benefits to patients around the world.